Sign In
Buy SKYE
$0.770
+0.0563 (+7.89%)
At Close: Jun 03, 2026
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Skye Bioscience, Inc. - SKYE
12:00pm, Friday, 05'th Jul 2024
NEW YORK, NY / ACCESSWIRE / July 5, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Skye Bioscience, Inc. ("Skye" or the "Company") (NASDAQ:SKYE). Such investors are advised to
Skye Bioscience Appoints Dr. Karen Smith to Board of Directors
07:00am, Wednesday, 03'rd Jul 2024
Seasoned industry veteran adds significant global biotech and biopharma experience to Skye's Board of Directors Seasoned industry veteran adds significant global biotech and biopharma experience to Sk
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Skye Bioscience, Inc. - SKYE
08:30am, Tuesday, 02'nd Jul 2024
NEW YORK , July 2, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Skye Bioscience, Inc. ("Skye" or the "Company") (NASDAQ: SKYE). Such investors are advised t
Skye Bioscience Added to Russell 2000® and Russell 3000® Indexes
07:00am, Monday, 01'st Jul 2024
SAN DIEGO, July 01, 2024 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biotechnology company focused on the discovery, development and commercialization of no
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Skye Bioscience, Inc. - SKYE
04:21pm, Sunday, 30'th Jun 2024
NEW YORK, June 30, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Skye Bioscience, Inc. (“Skye” or the “Company”) (NASDAQ: SKYE). Such investors are
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Skye Bioscience, Inc. - SKYE
02:45pm, Wednesday, 26'th Jun 2024
NEW YORK, NY / ACCESSWIRE / June 26, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Skye Bioscience, Inc. ("Skye" or the "Company") (NASDAQ:SKYE). Such investors are advised to
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Skye Bioscience, Inc. - SKYE
05:52pm, Monday, 24'th Jun 2024
NEW YORK , June 24, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Skye Bioscience, Inc. ("Skye" or the "Company") (NASDAQ: SKYE). Such investors are advised to
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Skye Bioscience, Inc. - SKYE
02:56pm, Saturday, 22'nd Jun 2024
NEW YORK, June 22, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Skye Bioscience, Inc. (“Skye” or the “Company”) (NASDAQ: SKYE). Such investors are
Perion Network Cuts Revenue Outlook, Joins Skye Bioscience And Other Big Stocks Moving Lower In Monday's Pre-Market Session
08:10am, Monday, 10'th Jun 2024
A more conservative goal of $100 monthly dividend income would require owning 306 shares of Altria Group.
Skye Bioscience to discontinue development of eye disease treatment
07:19am, Monday, 10'th Jun 2024
Skye Bioscience said on Monday it intends to discontinue development of its experimental eye disease treatment after it failed in a mid-stage study.
Skye Bioscience to Present at Jefferies Global Healthcare Conference
07:00am, Monday, 03'rd Jun 2024
SAN DIEGO, June 03, 2024 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biotechnology company focused on the discovery, development and commercialization of no
Skye Bioscience (SKYE) CEO on Drug Development
02:55pm, Tuesday, 14'th May 2024
Skye Bioscience (SKYE) focuses on developing proprietary molecules to treat diseases involving inflammatory, fibrotic, and metabolic conditions. CEO Punit Dhillon joins Nicole Petallides to discuss th
Poster presentation details screening approach allowing selection of candidate molecules applicable to dry eye disease and chronic ocular pain, with potential to identify therapeutic candidates with n
Skye Bioscience to Present Two Posters at Association for Research in Vision and Ophthalmology (ARVO) 2024 Annual Meeting
07:00am, Tuesday, 30'th Apr 2024
SAN DIEGO, April 30, 2024 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biotechnology company focused on the discovery, development and commercialization of n
Skye Bioscience to Present at Upcoming Investment Conferences
07:00am, Tuesday, 23'rd Apr 2024
SAN DIEGO, April 23, 2024 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biotechnology company focused on the discovery, development and commercialization of n
